Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

Detalhes bibliográficos
Autor(a) principal: Ramos, Rodrigo Nalio
Data de Publicação: 2021
Outros Autores: Picanço-Castro, Virginia, Oliveira, Théo Gremen Mimary de, Mendrone Junior, Alfredo, Santis, Gil Cunha de, Bonamino, Martin Hernan, Rocha, Vanderson
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/53500
Resumo: Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica em Patogênese e Terapia Dirigida em Onco-Imuno-Hematologia. São Paulo, SP, Brasil / Instituto D'Or de Ensino e Pesquisa. São Paulo, SP, Brasil.
id CRUZ_43fceb75ad814a913c2901175c8354b8
oai_identifier_str oai:www.arca.fiocruz.br:icict/53500
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Ramos, Rodrigo NalioPicanço-Castro, VirginiaOliveira, Théo Gremen Mimary deMendrone Junior, AlfredoSantis, Gil Cunha deBonamino, Martin HernanRocha, Vanderson2022-06-27T13:56:24Z2022-06-27T13:56:24Z2021RAMOS, Rodrigo Nalio et al. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. Hematology, Transfusion and Cell Therapy, v. 43, p. S46-S53, 2021. Suppl. 2.2531-1379https://www.arca.fiocruz.br/handle/icict/5350010.1016/j.htct.2021.09.007engElsevierAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapiesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica em Patogênese e Terapia Dirigida em Onco-Imuno-Hematologia. São Paulo, SP, Brasil / Instituto D'Or de Ensino e Pesquisa. São Paulo, SP, Brasil.Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. Hospital das Clínicas. Fundação Hemocentro de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica em Patogênese e Terapia Dirigida em Onco-Imuno-Hematologia. São Paulo, SP, Brasil / Fundação Pró-Sangue-Hemocentro de São Paulo. São Paulo, SP, Brasil.Fundação Pró-Sangue-Hemocentro de São Paulo. São Paulo, SP, Brasil.Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. Hospital das Clínicas. Fundação Hemocentro de Ribeirão Preto. Ribeirão Preto, SP, Brasil.Instituto Nacional de Câncer José Alencar Gomes da Silva. Divisão de Pesquisa Experimental e Translacional. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Presidência. Vice-Presidência de Pesquisa e Coleções Biológicas. Rio de Janeiro, RJ, Brasil.Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica em Patogênese e Terapia Dirigida em Onco-Imuno-Hematologia. São Paulo, SP, Brasil / Instituto D'Or de Ensino e Pesquisa. São Paulo, SP, Brasil / Fundação Pró-Sangue-Hemocentro de São Paulo. São Paulo, SP, Brasil.Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to develop new products based on CAR cells using T or other cell types. Production of CAR cells requires intensive work from the basic, pre-clinical to translational levels, aiming to overcome technical difficulties and failure in the production. At least five key common steps are needed for the manipulation of T-lymphocytes (or other cells), such as: cell type selection, activation, gene delivery, cell expansion and final product formulation. However, reproducible manufacturing of high-quality clinical-grade CAR cell products is still required to apply this technology to a greater number of patients. This chapter will discuss the present and future development of new CAR designs that are safer and more effective to improve this therapy, achieving more selective killing of malignant cells and less toxicity to be applied in the clinical setting.New technologiesCAR cell therapiesManufacturingGene deliveryinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83132https://www.arca.fiocruz.br/bitstream/icict/53500/1/license.txt33967fcc8ef681b8f5c2c34178ebc114MD51ORIGINALRamos_Rodrigo_etal_Presidência_2021.pdfRamos_Rodrigo_etal_Presidência_2021.pdfapplication/pdf694384https://www.arca.fiocruz.br/bitstream/icict/53500/2/Ramos_Rodrigo_etal_Presid%c3%aancia_2021.pdf35e976cf00f8a5ecfb95afb842c5b160MD52icict/535002022-06-27 10:59:00.338oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-27T13:59Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
spellingShingle Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
Ramos, Rodrigo Nalio
New technologies
CAR cell therapies
Manufacturing
Gene delivery
title_short Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_full Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_fullStr Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_full_unstemmed Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_sort Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
author Ramos, Rodrigo Nalio
author_facet Ramos, Rodrigo Nalio
Picanço-Castro, Virginia
Oliveira, Théo Gremen Mimary de
Mendrone Junior, Alfredo
Santis, Gil Cunha de
Bonamino, Martin Hernan
Rocha, Vanderson
author_role author
author2 Picanço-Castro, Virginia
Oliveira, Théo Gremen Mimary de
Mendrone Junior, Alfredo
Santis, Gil Cunha de
Bonamino, Martin Hernan
Rocha, Vanderson
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ramos, Rodrigo Nalio
Picanço-Castro, Virginia
Oliveira, Théo Gremen Mimary de
Mendrone Junior, Alfredo
Santis, Gil Cunha de
Bonamino, Martin Hernan
Rocha, Vanderson
dc.subject.en.pt_BR.fl_str_mv New technologies
CAR cell therapies
Manufacturing
Gene delivery
topic New technologies
CAR cell therapies
Manufacturing
Gene delivery
description Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica em Patogênese e Terapia Dirigida em Onco-Imuno-Hematologia. São Paulo, SP, Brasil / Instituto D'Or de Ensino e Pesquisa. São Paulo, SP, Brasil.
publishDate 2021
dc.date.issued.fl_str_mv 2021
dc.date.accessioned.fl_str_mv 2022-06-27T13:56:24Z
dc.date.available.fl_str_mv 2022-06-27T13:56:24Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv RAMOS, Rodrigo Nalio et al. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. Hematology, Transfusion and Cell Therapy, v. 43, p. S46-S53, 2021. Suppl. 2.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/53500
dc.identifier.issn.pt_BR.fl_str_mv 2531-1379
dc.identifier.doi.none.fl_str_mv 10.1016/j.htct.2021.09.007
identifier_str_mv RAMOS, Rodrigo Nalio et al. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. Hematology, Transfusion and Cell Therapy, v. 43, p. S46-S53, 2021. Suppl. 2.
2531-1379
10.1016/j.htct.2021.09.007
url https://www.arca.fiocruz.br/handle/icict/53500
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/53500/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/53500/2/Ramos_Rodrigo_etal_Presid%c3%aancia_2021.pdf
bitstream.checksum.fl_str_mv 33967fcc8ef681b8f5c2c34178ebc114
35e976cf00f8a5ecfb95afb842c5b160
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009213807394816

Registros relacionados